Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib in Japanese Ph+ CML
NCT00811070Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2007
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bosutinib in chronic myeloid leukemia (CML), sponsored by Pfizer. Primary endpoints: Dose-Limiting Toxicity at Day 28, Maximum Tolerated Dose at Day 28 and 1 more. Started Dec 2007; status: completed.
02
Drugs
bosutinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00811070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00811070.